Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Blue Trust Inc.

Blue Trust Inc. grew its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 362.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,203 shares of the biopharmaceutical company’s stock after purchasing an additional 943 shares during the quarter. Blue Trust Inc.’s holdings in Royalty Pharma were worth $32,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in RPRX. Versant Capital Management Inc boosted its position in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,043 shares during the period. Gladius Capital Management LP purchased a new position in Royalty Pharma in the second quarter valued at $32,000. Fidelis Capital Partners LLC acquired a new position in Royalty Pharma during the 1st quarter worth $46,000. EverSource Wealth Advisors LLC increased its holdings in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in Royalty Pharma by 4,335.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 2,688 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on RPRX shares. Citigroup cut their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group upped their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. StockNews.com downgraded Royalty Pharma from a “buy” rating to a “hold” rating in a report on Monday, October 28th. Finally, Morgan Stanley upped their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.67.

Royalty Pharma Trading Up 0.4 %

NASDAQ:RPRX opened at $27.10 on Friday. The stock has a 50-day simple moving average of $27.97 and a 200-day simple moving average of $27.57. The stock has a market cap of $16.08 billion, a P/E ratio of 23.98, a P/E/G ratio of 3.97 and a beta of 0.47. Royalty Pharma plc has a 1 year low of $25.20 and a 1 year high of $31.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the prior year, the firm posted $0.85 EPS. As a group, analysts anticipate that Royalty Pharma plc will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $0.21 dividend. The ex-dividend date is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.10%. Royalty Pharma’s dividend payout ratio (DPR) is presently 74.34%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.